This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders

Neurocrine Biosciences (NBIX) - FREE Research Report

Gorman Kevin Charles who is President and CEO at Neurocrine Biosciences sold 3,750 shares at $18.57 on Jan. 13, 2014. Following this transaction, the President and CEO owned 180,952 shares meaning that the stake was reduced by 2.03% with the 3,750-share transaction.

OBrien Christopher Flint who is Chief Medical Officer at Neurocrine Biosciences sold 6,750 shares at $18.88 on Jan. 13, 2014. Following this transaction, the Chief Medical Officer owned 96,544 shares meaning that the stake was reduced by 6.53% with the 6,750-share transaction.

Coughlin Timothy P who is Chief Financial Officer at Neurocrine Biosciences sold 1,750 shares at $18.56 on Jan. 13, 2014. Following this transaction, the Chief Financial Officer owned 97,874 shares meaning that the stake was reduced by 1.76% with the 1,750-share transaction.

Bozigian Haig P. who is Chief Development Officer at Neurocrine Biosciences sold 1,625 shares at $18.58 on Jan. 13, 2014. Following this transaction, the Chief Development Officer owned 78,579 shares meaning that the stake was reduced by 2.03% with the 1,625-share transaction.

Grigoriadis Dimitri E. who is Chief Research Officer at Neurocrine Biosciences sold 1,625 shares at $18.56 on Jan. 13, 2014. Following this transaction, the Chief Research Officer owned 77,058 shares meaning that the stake was reduced by 2.07% with the 1,625-share transaction.

Gano Kyle who is Chief Business Dev Officer at Neurocrine Biosciences sold 1,250 shares at $18.57 on Jan. 13, 2014. Following this transaction, the Chief Business Dev Officer owned 23,738 shares meaning that the stake was reduced by 5% with the 1,250-share transaction.

The shares most recently traded at $19.10, up $0.53, or 2.77% since the insider transaction. Historical insider transactions for Neurocrine Biosciences go as follows:

  • 4-Week # shares sold: 233,000
  • 12-Week # shares sold: 233,000
  • 24-Week # shares sold: 315,531

The average volume for Neurocrine Biosciences has been 1.0 million shares per day over the past 30 days. Neurocrine Biosciences has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 99.68% year-to-date as of the close of trading on Monday.

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Currently there are 11 analysts that rate Neurocrine Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBIX - FREE

TheStreet Quant Ratings rates Neurocrine Biosciences as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Neurocrine Biosciences Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

5 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 16,895.86 -147.04 -0.86%
S&P 500 1,958.36 -13.93 -0.71%
NASDAQ 4,454.3090 -39.0810 -0.87%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs